Nagi Bioscience
Private Company
Total funding raised: $3.7M
Overview
Nagi Bioscience is a platform and services company focused on revolutionizing aging and longevity research through automation and standardization of the C. elegans model. Its core offerings include the SydLab™ One, a fully automated benchtop platform for in-house use, and the Nagi™ C-Age and B-Age assays available via its contract research organization (CRO) services. By providing multi-dimensional, reproducible data in days rather than months, Nagi aims to de-risk and accelerate the development of therapeutic interventions and health claims. The company leverages over 15 years of domain expertise and Swiss engineering precision to position itself as a critical partner in the rapidly growing longevity sector.
Technology Platform
Automated, high-throughput in vivo testing platform using C. elegans for simultaneous measurement of lifespan, healthspan, and biological age, powered by proprietary hardware, software, and AI analytics.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Nagi competes with other C. elegans CROs and academic service cores, as well as providers of alternative model organism platforms (e.g., fruit fly, zebrafish). Its primary differentiation is the full automation, multi-endpoint measurement, and AI-powered biological age analysis integrated into a single workflow. It also competes indirectly with traditional rodent CROs by offering a faster, cheaper, ethical alternative for early-stage discovery.